迈瑞医疗(300760) - 2024 Q1 - 季度财报

Financial Performance - Revenue for Q1 2024 reached 9.37 billion RMB, a 12.06% increase compared to the same period last year[3] - Net profit attributable to shareholders rose to 3.16 billion RMB, up 22.90% year-over-year[3] - Revenue for Q1 2024 reached 9.37 billion yuan, a year-on-year increase of 12.06%[12] - Net profit attributable to shareholders in Q1 2024 was 3.16 billion yuan, up 22.90% year-on-year[12] - Total revenue for Q1 2024 reached 9.37 billion yuan, a 12.1% increase compared to 8.36 billion yuan in the same period last year[21] - Net profit attributable to the parent company rose to 2.78 billion yuan in Q1 2024, up from 2.47 billion yuan in the previous quarter[20] - Revenue from sales of goods and services reached 9,929,908,497.00, up from 8,855,109,506.00 in the previous period[24] - Net profit attributable to owners of the parent company was 3,159,898,674.00, up from 2,571,117,273.00[22] - Total profit for the period was 3,557,714,809.00, up from 2,887,600,375.00[22] Cash Flow and Liquidity - Operating cash flow surged by 114.85% to 2.86 billion RMB, driven by increased cash receipts from sales and services[5] - Cash and cash equivalents increased to 21.19 billion yuan at the end of Q1 2024, compared to 18.79 billion yuan at the beginning of the period[18] - Net cash flow from operating activities increased to 2,864,694,162.00, up 114.8% compared to the previous year[25] - Cash and cash equivalents at the end of the period reached 21,085,454,505.00, an increase of 2,417,035,227.00 from the beginning of the period[25] - Net cash used in investing activities was -400,882,530.00, an improvement from -497,127,763.00 in the previous year[25] - Net cash used in financing activities was -40,270,646.00, slightly higher than -37,237,728.00 in the previous year[25] Assets and Liabilities - Total assets grew by 6.03% to 50.83 billion RMB compared to the end of the previous year[3] - Shareholders' equity increased by 9.34% to 36.17 billion RMB[3] - Total assets increased to 50.83 billion yuan in Q1 2024, up from 47.94 billion yuan at the beginning of the period[20] - Accounts receivable grew to 3.65 billion yuan in Q1 2024, up from 3.30 billion yuan at the beginning of the period[18] - Inventory decreased slightly to 3.96 billion yuan in Q1 2024 from 3.98 billion yuan at the beginning of the period[19] - Total liabilities decreased to 14.40 billion yuan in Q1 2024 from 14.59 billion yuan at the beginning of the period[20] - The company's equity attributable to shareholders increased to 36.17 billion yuan in Q1 2024 from 33.09 billion yuan at the beginning of the period[20] Earnings and Shareholder Metrics - Basic earnings per share (EPS) increased by 22.80% to 2.6107 RMB[3] - Weighted average return on equity (ROE) improved by 1.40 percentage points to 9.12%[3] - Basic earnings per share increased to 2.6107 from 2.1260[23] - Diluted earnings per share rose to 2.6091 from 2.1247[23] - Total comprehensive income was 3,045,528,321.00, compared to 2,577,475,440.00[23] Non-Recurring Items and Accounting - Non-recurring gains and losses amounted to 122.89 million RMB, primarily from government subsidies and financial asset transactions[4] - The company reported no significant changes in accounting policies or restatements of prior financial data[3] - The company's first quarter report was unaudited[26] Shareholder Information - The top three shareholders are Smartco Development Limited (26.98%), Magnifice (HK) Limited (24.49%), and Hong Kong Securities Clearing Company (11.43%)[6] Research and Development - R&D investment in Q1 2024 was 1.03 billion yuan, accounting for 10.99% of revenue[13] - Cumulative patent applications reached 10,407, with 7,494 invention patents and 4,945 authorized patents, including 2,346 invention patents[14] - New products launched in Q1 2024 include CL-2600i automated chemiluminescence immunoassay analyzer and Resona/Nuewa I9 Elite Edition[13] International Market Performance - International market revenue grew nearly 30% in Q1 2024, with developing countries growing over 30%[12] Corporate Social Responsibility - Donated medical equipment worth $117,000 to Operation Smile Colombia in March 2024[15] - As of March 31, 2024, company's AEDs have successfully saved 228 cardiac arrest patients in public places in China[16] Acquisitions and Investments - The company completed the acquisition of Shenzhen Hui Tai Medical Equipment Co., Ltd. through its wholly-owned subsidiary Shenzhen Mindray Technology Holding Co., Ltd., with the shares transferred on April 15, 2024[17] Operating Costs and Expenses - Operating costs increased to 6.07 billion yuan in Q1 2024, up from 5.57 billion yuan in the same period last year[21] - Cash paid for employee compensation and benefits totaled 3,060,807,360.00, a 5.6% increase year-over-year[25] - Taxes paid decreased to 717,620,748.00, down 38.1% compared to the previous year[25] - Cash outflow for the purchase of fixed assets, intangible assets, and other long-term assets was 402,111,624.00, a 23.4% decrease year-over-year[25] Interest and Impairment - Interest income grew to 189,758,820.00 from 138,435,482.00[22] - Credit impairment losses increased to -66,413,250.00 from -47,319,982.00[22] - Asset impairment losses were -43,448,954.00, slightly higher than -42,555,992.00 in the previous period[22]